Sequential organocatalytic -hydroxy and Mukayama addition: A perspective for the synthesis of Orlistat

Sequential organocatalytic -hydroxy and Mukayama addition: A perspective for the synthesis of Orlistat

Silva, Rodrigo César da; Camargo, Leandro R. S.; Corrêa, Arlene Gonçalves; Paixão., Marcio Weber

Abstract:

Orlistat is a reduced form of the natural product lipstatin, which is an antiobesity agent marked under the tradename of Xenical approved by the FDA as the first over-the-counter weight-loss medication.

Orlistat is a reduced form of the natural product lipstatin, which is an antiobesity agent marked under the tradename of Xenical approved by the FDA as the first over-the-counter weight-loss medication.

Palavras-chave:

DOI: 10.5151/chempro-14bmos-R0314-1

Referências bibliográficas

• [1] 1Bertelsen, S; Dinér, P; Johansen; R. L; Jørgensen, K. A;. J. Am. Chem. Soc. 2007, 129, 1536.
• [2] 2 Schneider, C. Angew. Chem.; Int. Ed. 1998, 37, 1375.

Como citar:

Silva, Rodrigo César da; Camargo, Leandro R. S.; Corrêa, Arlene Gonçalves; Paixão., Marcio Weber; "Sequential organocatalytic -hydroxy and Mukayama addition: A perspective for the synthesis of Orlistat", p-314-314. In: In Blucher Chemistry Proceedings, São Paulo, v. 1, n. 1, Setembro.2013. São Paulo: Blucher, 2013.
ISSN 23184043, DOI 10.5151/chempro-14bmos-R0314-1